Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy
Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2015
|
| In: |
International immunology
Year: 2015, Jahrgang: 27, Heft: 1, Pages: 31-37 |
| ISSN: | 1460-2377 |
| DOI: | 10.1093/intimm/dxu089 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/intimm/dxu089 Verlag, Volltext: https://academic.oup.com/intimm/article/27/1/31/2950837 
|
| Verfasserangaben: | Zachary Zimmerman, Tapan Maniar and Dirk Nagorsen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1583843736 | ||
| 003 | DE-627 | ||
| 005 | 20220815060630.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181119s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/intimm/dxu089 |2 doi | |
| 035 | |a (DE-627)1583843736 | ||
| 035 | |a (DE-576)513843736 | ||
| 035 | |a (DE-599)BSZ513843736 | ||
| 035 | |a (OCoLC)1341023559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zimmerman, Zachary |e VerfasserIn |0 (DE-588)1171758774 |0 (DE-627)1040699383 |0 (DE-576)513843078 |4 aut | |
| 245 | 1 | 0 | |a Unleashing the clinical power of T cells |b CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy |c Zachary Zimmerman, Tapan Maniar and Dirk Nagorsen |
| 264 | 1 | |c January 2015 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.11.2018 | ||
| 500 | |a Advance access publication 19 September 2014 | ||
| 520 | |a Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies. | ||
| 700 | 1 | |a Maniar, Tapan |e VerfasserIn |0 (DE-588)1171759096 |0 (DE-627)1040699707 |0 (DE-576)513843671 |4 aut | |
| 700 | 1 | |a Nagorsen, Dirk |d 1974- |e VerfasserIn |0 (DE-588)12152471X |0 (DE-627)081364245 |0 (DE-576)183363094 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunology |d Oxford : Oxford Univ. Press, 1989 |g 27(2015), 1, Seite 31-37 |h Online-Ressource |w (DE-627)26687679X |w (DE-600)1467474-9 |w (DE-576)075144956 |x 1460-2377 |7 nnas |a Unleashing the clinical power of T cells CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy |
| 773 | 1 | 8 | |g volume:27 |g year:2015 |g number:1 |g pages:31-37 |g extent:7 |a Unleashing the clinical power of T cells CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/intimm/dxu089 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/intimm/article/27/1/31/2950837 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181119 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 12152471X |a Nagorsen, Dirk |m 12152471X:Nagorsen, Dirk |d 60000 |e 60000PN12152471X |k 0/60000/ |p 3 |y j | ||
| 999 | |a KXP-PPN1583843736 |e 3032694612 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"January 2015"}],"id":{"eki":["1583843736"],"doi":["10.1093/intimm/dxu089"]},"name":{"displayForm":["Zachary Zimmerman, Tapan Maniar and Dirk Nagorsen"]},"physDesc":[{"extent":"7 S."}],"relHost":[{"note":["Fortsetzung der Druck-Ausgabe"],"disp":"Unleashing the clinical power of T cells CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapyInternational immunology","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"26687679X","language":["eng"],"pubHistory":["1.1989 -"],"part":{"text":"27(2015), 1, Seite 31-37","volume":"27","extent":"7","year":"2015","issue":"1","pages":"31-37"},"titleAlt":[{"title":"II"}],"title":[{"subtitle":"II","title":"International immunology","title_sort":"International immunology"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["publ. in assoc. with The Japanese Society of Immunology"]},"origin":[{"publisher":"Oxford Univ. Press","dateIssuedKey":"1989","dateIssuedDisp":"1989-","publisherPlace":"Oxford"}],"id":{"issn":["1460-2377"],"zdb":["1467474-9"],"eki":["26687679X"]}}],"title":[{"title_sort":"Unleashing the clinical power of T cells","title":"Unleashing the clinical power of T cells","subtitle":"CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy"}],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Zimmerman, Zachary","given":"Zachary","family":"Zimmerman"},{"given":"Tapan","family":"Maniar","role":"aut","roleDisplay":"VerfasserIn","display":"Maniar, Tapan"},{"given":"Dirk","family":"Nagorsen","role":"aut","roleDisplay":"VerfasserIn","display":"Nagorsen, Dirk"}],"note":["Gesehen am 19.11.2018","Advance access publication 19 September 2014"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1583843736"} | ||
| SRT | |a ZIMMERMANZUNLEASHING2015 | ||